Clinical Trials Logo

Clinical Trial Summary

All patients will complete best standard of care radiation, temozolomide and bevacizumab (6 weeks). Within two weeks of completion of this initial treatment period, study patients will be fitted with the NovoTTF-100A System and treated continuously. They will be treated with TTFields for 12 months for an average of 18 hours per day. The patient may elect to take a treatment break for a total of 3 days per month, for each month and still be in compliance. This will consist of wearing four electrically insulated electrode arrays on the head. The patients will also continue with maintenance temozolomide/ bevacizumab.


Clinical Trial Description

This study will be carried out in two stages. The first stage will enroll a cohort of 22 patients. The FDA will review safety data of the first 15 patients during enrollment of the first cohort. Enrollment and interim analysis of the first cohort of patients will be completed within 15 months of study commencement. Upon FDA approval and favorable interim analysis followed by subsequent protocol/consent amendment (as applicable), the second stage will enroll a cohort of 24 patients and will be completed within 15 months of stage 2 commencement. The overall duration of the study is expected to be no longer than 30 months. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02343549
Study type Interventional
Source Wake Forest University Health Sciences
Contact
Status Terminated
Phase Phase 2
Start date January 2015
Completion date July 11, 2020

See also
  Status Clinical Trial Phase
Completed NCT05531695 - Exercise Study in Brain and CNS Cancer N/A
Completed NCT01135849 - B-Receptor Signaling in Cardiomyopathy N/A
Recruiting NCT03896958 - The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
Completed NCT01120639 - Phase 1-2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform Phase 1/Phase 2
Completed NCT00928226 - Study of Fractionated Stereotactic Radiosurgery to Treat Large Brain Metastases N/A